MYC aberrations, alone or concurrently with BCL2 aberrations, have been associated with inferior survival in DLBCL [9], warranting a study of MYC target gene products including MCT1 for therapy [10]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.